Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Ritchie

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Vascular Medicine (London, England)|May 12, 2016
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility studyGregory Piazza, Venkatesh Mani, Samuel Z Goldhaber, et al.
Allergy and Asthma Proceedings|January 26, 2011
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensityJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
The World Allergy Organization Journal|January 4, 2013
WAO Guideline for the Management of Hereditary AngioedemaTimothy Craig, Emel Aygören-Pürsün, Konrad Bork, et al.
Arerugi = [Allergy]|December 15, 2015
[WAO Guideline for the Management of Hereditary Angioedema]Timothy Craig, Emel Aygören Pürsün, Konrad Bork, et al.
Leukemia Research|April 20, 2016
Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid LeukemiaLalit Saini, Joseph Brandwein, Robert Turner, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2021
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION studyPaolo Ventura, Herbert L Bonkovsky, Laurent Gouya, et al.
Frontiers in Medicine|August 8, 2024
Rationale and design of the multi organ inflammation with serial testing study: a comprehensive assessment of functional and structural abnormalities in patients with recovered COVID-19D Ian Paterson, James A White, Christian Beaulieu, et al.
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Vascular Medicine (London, England)|May 12, 2016
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility studyGregory Piazza, Venkatesh Mani, Samuel Z Goldhaber, et al.
Allergy and Asthma Proceedings|January 26, 2011
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensityJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
The World Allergy Organization Journal|January 4, 2013
WAO Guideline for the Management of Hereditary AngioedemaTimothy Craig, Emel Aygören-Pürsün, Konrad Bork, et al.
Arerugi = [Allergy]|December 15, 2015
[WAO Guideline for the Management of Hereditary Angioedema]Timothy Craig, Emel Aygören Pürsün, Konrad Bork, et al.
Leukemia Research|April 20, 2016
Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid LeukemiaLalit Saini, Joseph Brandwein, Robert Turner, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2021
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION studyPaolo Ventura, Herbert L Bonkovsky, Laurent Gouya, et al.
Frontiers in Medicine|August 8, 2024
Rationale and design of the multi organ inflammation with serial testing study: a comprehensive assessment of functional and structural abnormalities in patients with recovered COVID-19D Ian Paterson, James A White, Christian Beaulieu, et al.
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Pageof 7